Literature DB >> 9407629

Radiotherapy of primary malignant brain tumors.

D A Larson1, W M Wara.   

Abstract

Radiotherapy is usually recommended for patients with a primary malignant brain tumor. The foundation for its use is grounded on the results of randomized trials for malignant gliomas which have demonstrated a relationship between survival and external beam radiation dose. Although similar trials have not been performed for most other primary intracranial tumors, radiation oncologists treat them in a similar fashion, delivering the highest possible dose consistent with acceptable levels of normal tissue damage. In most cases, focal therapy is required, using modern three-dimensional treatment planning and delivery--with whole brain or craniospinal therapy used only for infrequently encountered clinical presentations. With modern planning, the volume of normal tissue subjected to possible radiation damage can be minimized. Radiation effects in normal tissues typically occur months to years after treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9407629     DOI: 10.1002/(sici)1098-2388(199801/02)14:1<34::aid-ssu5>3.0.co;2-3

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  3 in total

1.  Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.

Authors:  Ilwoo Park; Gregory Tamai; Michael C Lee; Cynthia F Chuang; Susan M Chang; Mitchel S Berger; Sarah J Nelson; Andrea Pirzkall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

Review 2.  Advances in stereotactic radiosurgery for brain neoplasms.

Authors:  M D Weil
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

3.  Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft.

Authors:  Emilie Allard; Delphine Jarnet; Anne Vessières; Sandrine Vinchon-Petit; Gérard Jaouen; Jean-Pierre Benoit; Catherine Passirani
Journal:  Pharm Res       Date:  2009-11-12       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.